MONTREAL, Sept. 13, 2023 (GLOBE NEWSWIRE) — DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round of $80m USD to conduct the Dal-GenE-2 confirmatory trial in North America under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA…
Read More
About The Author
